183 related articles for article (PubMed ID: 37653115)
21. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Zhang Q; Tang L; Zhou Y; He W; Li W
Front Immunol; 2021; 12():663986. PubMed ID: 34122422
[TBL] [Abstract][Full Text] [Related]
22. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
Yin J; Wu Y; Yang X; Gan L; Xue J
Front Immunol; 2022; 13():830631. PubMed ID: 35464480
[TBL] [Abstract][Full Text] [Related]
23. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
24. Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report.
Cheng Y; Wang XM; Hu Q; Sun K; Zhao X; Zhang M; Wang G; Wang H; Xiong Y
Front Immunol; 2022; 13():899971. PubMed ID: 35911750
[TBL] [Abstract][Full Text] [Related]
25. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
[TBL] [Abstract][Full Text] [Related]
26. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Wang YN; Lou DF; Li DY; Jiang W; Dong JY; Gao W; Chen HC
Oncol Lett; 2020 Jul; 20(1):611-622. PubMed ID: 32565986
[TBL] [Abstract][Full Text] [Related]
27. Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysis.
Frost N; Unger K; Blum TG; Misch D; Kurz S; Lüders H; Olive E; Raspe M; Hilbrandt M; Koch M; Böhmer D; Senger C; Witzenrath M; Grohé C; Bauer T; Modest DP; Kollmeier J
Lung Cancer; 2023 May; 179():107184. PubMed ID: 37040677
[TBL] [Abstract][Full Text] [Related]
28. Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report.
Miao K; Xu Y; Xu W; Zhang Y; Xu Y; Tian X; Zhang L
Thorac Cancer; 2021 Aug; 12(15):2214-2216. PubMed ID: 34145962
[TBL] [Abstract][Full Text] [Related]
29. Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma.
Strippoli S; Fucci L; Negri A; Putignano D; Cisternino ML; Napoli G; Filannino R; De Risi I; Sciacovelli AM; Guida M
J Transl Med; 2020 Dec; 18(1):473. PubMed ID: 33302981
[TBL] [Abstract][Full Text] [Related]
30. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M; Spakowicz D; Zhao S; Patel SH; Johns A; Grogan M; Miah A; Husain M; He K; Bertino EM; Shields PG; Wei L; Carbone DP; Otterson GA; Presley CJ; Owen DH
Cancer Immunol Immunother; 2020 Nov; 69(11):2403-2408. PubMed ID: 32728772
[TBL] [Abstract][Full Text] [Related]
31. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
[TBL] [Abstract][Full Text] [Related]
32. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.
Reuss JE; Suresh K; Naidoo J
Curr Oncol Rep; 2020 May; 22(6):56. PubMed ID: 32415399
[TBL] [Abstract][Full Text] [Related]
33. [Establish a whole-process comprehensive surveillance management mode for immune checkpoint inhibitor pneumonitis].
Xu Y; Pan RL; Huang H; Wang MZ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Aug; 57(8):1176-1180. PubMed ID: 37574309
[TBL] [Abstract][Full Text] [Related]
34. Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis.
Zhou C; Yang Y; Lin X; Fang N; Chen L; Jiang J; Deng H; Deng Y; Wan M; Qiu G; Sun N; Wu D; Long X; Zhong C; Xie X; Xie Z; Liu M; Ouyang M; Qin Y; Petrella F; Fiorelli A; Bravaccini S; Kataoka Y; Watanabe S; Goto T; Solli P; Igai H; Saito Y; Tsoukalas N; Nakada T; Li S; Chen R
Front Immunol; 2022; 13():935779. PubMed ID: 35967342
[TBL] [Abstract][Full Text] [Related]
35. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
Wang W; Wang Q; Xu C; Li Z; Song Z; Zhang Y; Cai X; Zhang S; Lian B; Li W; Liu A; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Xie C; Zhang J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Lan F; Feng H; Wang L; Yao W; Shi X; Huang J; Chen H; Zhang Y; Sun P; Wan B; Pang F; Xu Z; Wang K; Xia Y; Ye M; Wang D; Wei Q; Feng S; Zhou J; Zhang J; Lv D; Gao W; Kang J; Yu G; Liang X; Yu C; Shi L; Yang N; Wu L; Hong Z; Hong W; Fang M; Zhang Y; Lu Y; Wang G; Ma S; Si L; Fang W; Song Y
Thorac Cancer; 2022 Dec; 13(23):3420-3430. PubMed ID: 36268845
[TBL] [Abstract][Full Text] [Related]
36. Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: clinical characteristics and risk factors.
Zhang C; Gao F; Jin S; Gao W; Chen S; Guo R
Ann Palliat Med; 2020 Nov; 9(6):3957-3965. PubMed ID: 33302658
[TBL] [Abstract][Full Text] [Related]
37. A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case-Control Study.
Deng H; Deng J; Lin X; Guan W; Lin Z; Qiu Y; Yang Y; Wu J; Qiu G; Sun N; Zhou M; Deng J; Xie X; Xie Z; Liu M; Qin Y; Zhou Y; Zhou C
Clin Drug Investig; 2023 May; 43(5):347-357. PubMed ID: 37097608
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
